KRAS Neoantigen Nanovaccine (The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School)

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameKRAS Neoantigen Nanovaccine (The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A